Lasofoxifene

CAS : 180916-16-9

Ref. TR-L176500

Informations sur le produit

• Nom: Lasofoxifene
• Synonymes: 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-, (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, (-)-cis-6(S)-Phenyl-5(R)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol, (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol, (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol, (5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-, Cp-336,156

Description

Applications A next-generation selective estrogen receptor modulator for treating disorders associated with increased bone turnover and osteopenia.
References Baumann, R., et al.: Biochem. Pharmacol., 55, 841 (1998), Ammann, P., et al.: Osteoporos Int., 10, 369 (1999), Alexandersen, P., et al.: J. Clin. Endocrinol. Metab., 86, 755 (2001), Bourrin, S., et al.: Bone, 30, 195 (2002), Buzdar, A., et al.: J. Clin. Oncol., 21, 1007 (2003),

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 413.55
• Formule: C₂₈H₃₁NO₂
• Couleur/Forme: Neat
• InChI: InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
• Code InChI: InChIKey=GXESHMAMLJKROZ-IAPPQJPRSA-N
• SMILES: Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1